Treatment outcomes with open-capsule budesonide (n=19)
| Characteristics | No. of patients |
| Clinical response | 18 (95%) |
| Days from OCB initiation to clinical response, median (IQR) | 4 (1–7) |
| Clinical remission | 15 (79%) |
| Days from OCB initiation to clinical remission, median (IQR) | 27 (8–36) |
| Corticosteroid-free remission | 11 (58%) |
| Restoration of pre-irEnteritis weight on OCB cessation | 14 (74%) |
| Weight gain (kg) from OCB initiation to cessation, median (range) | 4 (0–19) |
| Weight gain (kg) from irEnteritis nadir to remission, median (range) | 5 (1–19) |
| Days from irEnteritis onset to OCB initiation, median (IQR) | 62 (27–134) |
| Days from most recent endoscopic evaluation to OCB initiation, median (IQR) | 16 (10–44) |
| Adverse events from OCB | 1 (1%) |
| Duration (days) of OCB treatment, median (IQR) | 57 (26–89) |
| irEnteritis relapse after OCB treatment | 7 (37%) |
| Days from OCB cessation to irEnteritis relapse, median (IQR) | 26 (4–57) |
| Treatments for irEnteritis relapse on OCB (n=7) | |
| Systemic corticosteroids alone | 1 (14%) |
| Infliximab | 3 (43%) |
| Vedolizumab | 5 (71%) |
| Response after restarting OCB for irEnteritis relapse (n=2) | |
| Clinical response | 2 (100%) |
| Clinical remission | 1 (50%) |
irEnteritis, immune-related enteritis; OCB, open-capsule budesonide.